Nexus Nplate® (romiplostim)

Welcome to Nplate^® (romiplostim) NEXUS

The Nplate^® NEXUS Program Connects You With Nplate^® Access, Support, Education, and Safety Monitoring.

Amgen is committed to encouraging quality patient care. The Nplate^® NEXUS program is designed to facilitate provider education and monitor safety to assure quality patient care.

Nplate^® is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins
or splenectomy.

Nplate^® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate^® should not be used in an attempt to normalize platelet counts.

IMPORTANT SAFETY INFORMATION

Serious adverse reactions associated with Nplate^® in clinical studies were bone marrow reticulin deposition
and worsening thrombocytopenia after Nplate^® discontinuation. Additional risks include Bone Marrow Fibrosis, Thrombotic/Thromboembolic Complications, Lack or Loss of Response to Nplate^®, and Hematological Malignancies and Progression of Malignancy in Patients with a Pre-existing Hematological Malignancy or Myelodysplastic Syndrome (MDS).

Nplate^® is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than chronic ITP.

Nplate^® is available only through a restricted distribution program called Nplate^® NEXUS (Network of Experts Understanding and Supporting Nplate^® and Patients) Program.

In the placebo-controlled studies, headache was the most commonly reported adverse drug reaction.